Clinical characteristics, demography and outcome trends of adjuvant anthracycline- and taxane based chemotherapy regimen in early-stage breast cancer- A single centre experience of 264 patients

World Cancer Summit 2018

July 02-03, 2018 Bangkok, Thailand

Ashok K Vaid

Medanta Cancer Institute, India

Posters & Accepted Abstracts: J Cancer Sci Ther

Abstract :

Background: Anthacycline- and Taxane based chemotherapy regimen remains the gold standard for the adjuvant chemotherapy treatment of early-stage breast cancer. However, the knowledge on the use and effectiveness of this treatment regimen in realworld setting is limited. This study examined the treatment trends of adjuvant anthracycline- and taxane based chemotherapy regimen in the routine clinical practice at a single tertiary care cancer centre in India. Methods: Patients with histologically or cytologically confirmed early breast cancer who underwent primary breast surgery followed by adjuvant treatment with anthracycline- and taxane based chemotherapy regimen at Medanta Cancer Institute between 2010 and 2015 were included in the study. Data on clinical characteristics and treatment details was collected from the patient�s medical records. Invasive Disease Free Survival (IDFS) was taken as the primary efficacy endpoint. Results: Two sixty four patients were included in the analysis. There were 262 women and 2 men with a median age of 50 years (range 24-76 years). Among the 262 women, 107 (40.5%) were premenopausal and 157 (59.5%) had reached menopause. The laterality of breast was left in 144 (54.5%), right in 116 (43.9%) and bilateral in 4 (1.6%) patients respectively. 93 (35.2%) patients underwent breast-conserving surgery (BCS) and 171 (64.7%) modified radical mastectomy (MRM). Grade of tumor was 1, 2 and 3 in 19, 140 and 105 patients respectively. Tumor Focality was single in 215 (81.4%) patients and multiple in 49 (18.6%) patients respectively. The median number of nodes dissected were 17 (range 1-74) with > 4 positive nodes in 60 (22.7%) patients. Estrogen, progesterone and HER-2 receptors were positive in 154 (58.3%), 143 (54.2%) and 8 (3%) patients respectively whereas 102 (38.6%) patient had triple negative disease. Although the overall HER-2 receptor positivity in our breast cancer data is 25.2% (181 out of 717 patients), the above data of 3% represent the subset of patients that were treated with anthracycline-and taxane based chemotherapy regimen. At a median follow-up of 37 months (range 1-99 months), the IDFS was 83.6%. Conclusion: The preliminary results of this study confirm the clinical utility of anthacyclines- and taxanes based chemotherapy regimen in the adjuvant chemotherapy treatment of early-stage breast cancer. Further follow-up will be undertaken to assess the long term utility of this treatment regimen.